【国家药监局批准艾曲帕米鼻喷雾剂上市】近日,国家药品监督管理局批准Milestone Pharmaceuticals Inc.申报的1类创新药艾曲帕米鼻喷雾剂上市,该药用于治疗成人阵发性室上性心动过速急性症状发作,转复为窦性心律。该药品上市为患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.